Clay Siegall, the long-standing CEO of Seagen, a Bothell biotech company known for cancer therapies, resigned this week after his arrest on April 23, 2022, due to domestic violence allegations. His wife reported physical assaults resulting in injuries and sought a protection order, which was granted. Seagen's board has initiated an investigation with an independent law firm, although Siegall denies the claims and is engaged in divorce proceedings. The company emphasizes its commitment to employee conduct and condemns domestic violence. Roger Dansey, the chief medical officer, will serve as interim CEO to ensure leadership continuity.

Seagen's financial health remains strong, with revenues exceeding $1. 6 billion in 2021, indicating potential for future growth. Siegall's resignation was framed as a mutual decision with the board for the company's best interests, not as a direct result of the investigation's findings. Seagen continues to focus on developing innovative cancer treatments and maintaining its reputation as a leading biotech firm.